PDSB jumps on JAMA data and Nant Capital PIPE
Alpha Vantage · StocksToTrade · · AI-summarised by FinFlash
PDS Biotechnology shares jumped 13.08% after Phase 2 data for its HPV16-targeted immunotherapy PDS0101 was published in JAMA Oncology, showing a 36% objective response rate and 39.3-month median overall survival. The company also secured an Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context